Key figures

What does the final I-CARE cohort represent in a few figures ?

For the patients

patient researcher’s actors of this project

patients contacted for the study purposes

eDiaries sent to patients

eDiaries completed by patients

For the investigators

assessable patients

patient – years

of compliance in the ePRO completion

medical reports collected for the coding

We did it !!!

Analysis in progress. Thanks to all patients, investigators, partners

31/03/2022 : End of Study for all patients
16/05/2022 : last patient out
17/03/2023 : database lock

508 Participating Investigators
305 Study Nurses
22 contributors (GETAID and external contributors)
15 participating countries

Total included population

Total number of included patients :

13 262

France : 3757
United Kingdom : 2985
Italy : 1051
Greece : 961
Spain : 1026
Belgium : 601
Germany : 560
Denmark : 420

Israel : 465
Ireland : 389
Portugal : 382
Hungary : 317
Netherland : 139
Sweden : 114
Poland : 91

Assessable population (= Patients with at least 2 ePro completed)

Repartition of total number of assessable patients per country (10 206 patients)

Repartition of assessable population per treatment (10206 patients)

Group 1: Patients having never received biological agents or immunosuppressant (all 5-ASA and steroids formulations are permitted) and then (protocol amendment n°7) patients receiving no ongoing immunosuppressant and biologic agent at inclusion in I-CARE study (all previous medication accepted) (all 5-ASA and steroids formulations are permitted)
Group 2: Patients receiving thiopurines alone
Group 3: Patients treated with anti-TNF therapy alone without any concomitant immunosuppressant
Group 4: Patients treated with anti-TNF therapy in combination with thiopurines or methotrexate
Group 5a: Patients treated with vedolizumab alone (without any concomitant immunosuppressant)
Group 5b: Patients treated with vedolizumab in combination with thiopurines or methotrexate.
Group 6: Patients treated with ustekinumab with or without any concomitant medications.